Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance

Doğru, Teoman; Sönmez, Alper; Taşçı, İlker; Bozoğlu, Ergün; Yılmaz, Mahmut İlker; Genç, Halil; Erdem, Gökhan; Gök, Mahmut; Bingol, Necati; Kılıç, Selim; Özgürtaş, Taner; Bingol, Sezin

doi:10.1016/j.diabres.2006.07.031

Cited by 177 publications

(147 citation statements)

References 25 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…In humans, the normal fasting PBEF level is 10-40 ng/ml [1][2][3][4][5], which equals 180-700 pmol/l for this 55 kDa protein, 3.6-14 times the concentration of the normal fasting insulin level (50 pmol/l). If PBEF could act with the same efficacy as insulin [1], it should contribute importantly to the regulation of glucose metabolism.…”

Section: Discussionmentioning

confidence: 94%

“…Visfatin was also shown to mimic the effect of insulin with the same efficacy in rodent cells in vitro and in mouse models [1]. However, subsequent studies in human subjects reported conflicting results with regard to its relation with adiposity [2][3][4], subcutaneous or visceral fat [2,3], and insulin resistance [3][4][5], suggesting that the role of this protein in the development of obesity and insulin resistance remains unclear.…”

Section: Introductionmentioning

confidence: 99%

“…In this case, familial combined hyperlipidemia (FCHL) family relatives were chosen because FCHL is a disorder of lipoprotein metabolism in the presence of insulin resistance, and it is known that the accumulation of abdominal fat, especially visceral fat, is highly prevalent in FCHL families [11]. To avoid the influence of type 2 diabetes [4,5], only non-diabetic subjects were enrolled in this study.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

Wang

Greevenbroek

Bouwman

et al. 2007

Pflugers Arch - Eur J Physiol

View full text Add to dashboard Cite

Visfatin with the official gene name pre-B cell colony-enhancing factor 1 (PBEF) and the protein name nicotinamide phosphoribosyltransferase (NAMPT) is a recently discovered adipocyte-secreted protein that was shown by some to be associated with visceral fat and insulin resistance. To explore the link between PBEF/ NAMPT/visfatin and lipid metabolism, we analyzed the relation of its plasma level with several parameters of adiposity, insulin resistance and the circulating blood lipid profile in a group of general population (n=40) and a group of subjects who are genetically predisposed to insulin resistance and hyperlipidemia (n=35). In both groups and pooled cohort, PBEF/NAMPT/visfatin lacked association with whole body adiposity, but correlated positively with HDL-cholesterol and negatively with triglycerides. The data suggested a negative correlation of the PBEF level with visceral fat and insulin resistance. But this negative correlation completely disappeared after adjustment for lipid profile. We concluded that circulating PBEF/NAMPT/ visfatin level is an indicator of beneficial lipid profile in non-diabetic Caucasian subjects. The relation to lipid metabolism does not depend on visceral obesity and insulin resistance, but may be linked to its enzymatic function in NAD metabolism.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

Wang

Greevenbroek

Bouwman

et al. 2007

Pflugers Arch - Eur J Physiol

View full text Add to dashboard Cite

show abstract

“…Visfatin levels increased in Asian Indians with type 2 diabetes mellitus, but the association was lost after adjusting for obesity [10]. In another study, visfatin levels were reported to be higher in the diabetic group than the controls, but there was no significant difference in visfatin levels between the impaired glucose-tolerant group and the healthy controls [11]. Visfatin levels were correlated with HbA1c in patients with type 2 diabetes and lowered by intensive glycemic control [12].…”

Section: Introductionmentioning

confidence: 89%

Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus

Akbarzadeh

Nabipour

Jafari

et al. 2012

Diabetes Research and Clinical Practice

View full text Add to dashboard Cite

“…It has been shown that visfatin binds to the insulin receptor at a distinct site, and exerts its hypoglycemic activity by reducing glucose release from hepatocytes, and stimulating glucose utilization in peripheral tissues (6). The synthesis and secretion of visfatin are shown to be up-regulated in several animal models of obesity, as well as human with abdominal obesity and/or type 2 diabetes mellitus (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats

Gao

Wang

Pan

et al. 2014

Arq Bras Endocrinol Metab

View full text Add to dashboard Cite

Objective: Visfatin is a recently discovered adipocytokine that contributes to glucose and obesityrelated conditions. Until now, its responses to the insulin-sensitizing agent metformin and to exercise are largely unknown. We aim to investigate the impact of metformin treatment and/or swimming exercise on serum visfatin and visfatin levels in subcutaneous adipose tissue (SAT), peri-renal adipose tissue (PAT) and skeletal muscle (SM) of high-fat-induced obesity rats. Materials and methods:Sprague-Dawley rats were fed a normal diet or a high-fat diet for 16 weeks to develop obesity model. The high-fat-induced obesity model rats were then randomized to metformin (MET), swimming exercise (SWI), or adjunctive therapy of metformin and swimming exercise (MAS), besides high-fat obesity control group and a normal control group, all with 10 rats per group. Zoometric and glycemic parameters, lipid profile, and serum visfatin levels were assessed at baseline and after 6 weeks of therapy. Visfatin levels in SAT, PAT and SM were determined by Western Blot. Results: Metformin and swimming exercise improved lipid profile, and increased insulin sensitivity and body weight reduction were observed. Both metformin and swimming exercise down-regulated visfatin levels in SAT and PAT, while the adjunctive therapy conferred greater benefits, but no changes of visfatin levels were observed in SM. Conclusion: Our results indicate that visfatin down-regulation in SAT and PAT may be one of the mechanisms by which metformin and swimming exercise inhibit obesity.Arq Bras Endocrinol Metab. 2014;58(1):42-7 Keywords Endocrinology; metabolic syndrome; adipocytokine RESUMO Objetivo: A visfatina é uma adipocina recentemente descoberta que contribui com as condições relacionadas à glicose e à obesidade. Até hoje, pouco se sabe da sua resposta à metformina, um agente sensibilizador de insulina, e ao exercício. Nosso objetivo foi investigar o impacto do tratamento com metformina e/ou da natação sobre a visfatina no soro e no tecido adiposo subcutâneo (TAS), tecido adiposo perirrenal (TAP) e músculo esquelético (ME) em ratos com obesidade induzida por dieta com alto teor de gordura. Materiais e métodos: Ratos Sprague-Dawley foram alimentados com uma dieta normal ou com alto teor de gordura por 16 semanas para o desenvolvimento de um modelo de obesidade. Os ratos do modelo de obesidade foram, então, randomizados para a metformina, natação ou terapia de combinação com metformina e natação, além do grupo controle de obesidade induzida por alto teor de gordura e do grupo controle normal. Cada grupo apresentava 10 ratos. Parâmetros zoométricos e glicêmicos, perfil lipídico e níveis de visfatina sérica foram avaliados no momento inicial e após seis semanas de tratamento. Os níveis de visfatina em TAS, TAP e ME foram determinados por Western Blot. Resultados: A metformina e a natação melhoraram o perfil lipídico e aumentaram a sensibilidade à insulina, com redução do peso corporal. Tanto a metformina quanto a natação levaram à regulação para baixo do...

show abstract

Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance

Cited by 177 publications

References 25 publications

The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

The circulating PBEF/NAMPT/visfatin level is associated with a beneficial blood lipid profile

Serum visfatin and vaspin levels in normoglycemic first-degree relatives of Iranian patients with type 2 diabetes mellitus

Impact of metformin treatment and swimming exercise on visfatin levels in high-fat-induced obesity rats

Contact Info

Product

Resources

About